Telmisartan versus EnalapRil In heart failure with redUced ejection fraction patients with Moderately impaired kidney Functions; randomized controlled trial: “TRIUMF trial”

BACKGROUND: When heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) co-exist, Renin angiotensin-aldosterone system inhibitors (RAASi) are often underutilized for the fear of worsening renal function (WRF). Telmisartan is a RAASi characteristic for a favorable renal...

Descripción completa

Detalles Bibliográficos
Autores principales: Samir, Ahmad, Aboel-Naga, Salma, Shehata, Ahmed, Abdelhamid, Magdy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10409965/
https://www.ncbi.nlm.nih.gov/pubmed/37552407
http://dx.doi.org/10.1186/s43044-023-00398-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10409965/
https://www.ncbi.nlm.nih.gov/pubmed/37552407
http://dx.doi.org/10.1186/s43044-023-00398-7

Ejemplares similares